Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PARIS, June 09, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO) (hereafter “Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the...
-
PARIS, May 31, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of...
-
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch of a new study to evaluate the abrogation of...
-
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitorsIntroducing OX400, a new generation of PARP interfering cancer drug candidates PARIS, April 08, 2021 (GLOBE NEWSWIRE) -- Onxeo...
-
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients with advanced solid tumors.The good safety profile of AsiDNA™ is confirmed...
-
PARIS, France, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), hereafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the...
-
Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancerFirst results from Revocan are expected early 2021 PARIS, Oct. 21, 2020 ...
-
The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, provides financial visibility into Q1 2022Patient inclusion process has started...
-
PARIS, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
-
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration in the treatment of TNBC and chemo-resistant lung cancer, alone or in...